Alembic Pharma News and Updates

Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 3
Author: Motilal Oswal

Keep track of all breaking news on Alembic Pharma from all sources in a single place.

Alembic Pharmaceuticals Ltd.

16 Apr 2026

755.00

-0.80%

Alembic Pharmaceuticals gets USFDA nod for generic cancer, arthritis treatment injection

Business Line

The final approval granted is for the abbreviated new drug application of Methotrexate injection of strengths 50 mg/2 ml multi-dose Vials and 1g/40 ml single-dose vials

Number of FII/FPI investors decreased from 195 to 188 in Mar 2026 qtr

Alembic Pharmaceuticals Ltd.

07 Apr 2026

755.00

-0.80%

Alembic Pharma receives USFDA approval for generic dapagliflozin tablets

Business Standard

Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic version of dapagliflozin tablets used to control blood sugar levels in people with type-2 diabetes. The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of dapagliflozin tablets of strengths 5 mg and 10 mg, Alembic Pharmaceuticals Ltd said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Farxiga Tablets, 5 mg and 10 mg, of AstraZeneca AB (AstraZeneca), it added. Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Dapagliflozin Tablets, 5 mg and 10 mg. With this approval, Alembic is eligible for 180 days of shared generic drug marketing exclusivity, the company said. Dapagliflozin tablet is indicated to reduce the risk of hospitalisation for heart failure in adults with...

Alembic Pharmaceutic.. has an average target of 1022.00 from 4 brokers.

Alembic Pharma gains 4% on getting USFDA nod for Dapagliflozin tablets

Business Standard | 07 Apr 2026

Alembic Pharmaceuticals Ltd.

06 Feb 2026

755.00

-0.80%

Alembic Pharmaceuticals gets nod for generic Parkinson's treatment tablets

Business Standard

Alembic Pharmaceuticals Ltd on Friday said it has received approval from the US health regulator for its generic version of Carbidopa, Levodopa and Entacapone tablets used in treatment of Parkinson's disease. The approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of Carbidopa, Levodopa and Entacapone tablets of strengths 12.5 mg/50 mg/200 mg; 18.75 mg/75 mg/200 mg; 25 mg/100 mg/200 mg; 31.25 mg/125 mg/200 mg; 37.5 mg/150 mg/200 mg; and 50 mg/200 mg/200 mg, Alembic Pharmaceuticals Ltd said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo tablets of similar strengths of Orion Corporation, it added. Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson's disease, the company said.

Number of FII/FPI investors decreased from 195 to 188 in Mar 2026 qtr

Alembic Pharma shares slide 4% on Q3 profit miss; is it a good time to buy?

Business Standard | 06 Feb 2026 1 more

Alembic Pharmaceuticals Ltd.

05 Feb 2026

755.00

-0.80%

to see Rapid results content

Alembic Pharmaceuticals Ltd.

05 Feb 2026

755.00

-0.80%

Ex-US and Animal Health perform, while DF and US lag

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) exhibited in-line revenue with a slight miss on EBITDA/PAT for the quarter. While ex-US export growth was strong for the quarter, it was offset by moderate YoY growth in domestic formulation (DF) and US sales.

Alembic Pharmaceuticals Ltd. is trading above its 50 day SMA of 720.7

Alembic Pharmaceuticals Ltd.

27 Jan 2026

755.00

-0.80%

Alembic Pharmaceuticals gets USFDA nod for generic eye treatment drug

Business Standard

Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic version of Difluprednate ophthalmic emulsion used to treat eye inflammation and pain due to surgery. The approval granted by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) Difluprednate ophthalmic emulsion of strength 0.05 per cent, Alembic Pharmaceuticals said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product, Durezol ophthalmic emulsion, 0.05 per cent, of Sandoz Inc, it added. Difluprednate ophthalmic emulsion is indicated for the treatment of inflammation and pain associated with ocular surgery and also indicated for the treatment of endogenous anterior uveitis, a type of disorder of the eye.

Number of FII/FPI investors decreased from 195 to 188 in Mar 2026 qtr

Alembic Pharmaceuticals Ltd.

12 Jan 2026

755.00

-0.80%

Alembic Pharmaceuticals gets USFDA tentative nod for generic cancer treatment drug

Business Line

The tentative approval granted by the US Food & Drug Administration (USFDA) is for its supplemental abbreviated new drug application (sANDA) Bosutinib tablets of strength 400 mg, Alembic said in a regulatory filing

Alembic Pharmaceutic.. has an average target of 1022.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

11 Dec 2025

755.00

-0.80%

Alembic gets USFDA nod for generic eye infection treatment suspension

Business Standard

Alembic Pharmaceuticals Ltd on Thursday said it has received final approval from the US health regulator for its generic version of Loteprednol Etabonate and Tobramycin ophthalmic suspension used for treatment of eye infection. The approval granted by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Loteprednol Etabonate and Tobramycin Ophthalmic Suspension of strength 0.5 per cent/0.3 per cent (5 mL and 10 mL), Alembic Pharmaceuticals Ltd said in a regulatory filing. Alembic was granted a Competitive Generic Therapy (CGT) designation for this application. With this approval, Alembic is eligible for 180 days of CGT exclusivity upon commercialisation, it added. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5 per cent/0.3 per cent, of Bausch & Lomb Incorporated, the company said. Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5 per cent/0.3 per cent, is...

Number of FII/FPI investors decreased from 195 to 188 in Mar 2026 qtr

Alembic Pharmaceuticals gets USFDA nod for generic eye infection treatment suspension

Business Line | 11 Dec 2025

Alembic Pharmaceuticals Ltd.

07 Nov 2025

755.00

-0.80%

Alembic Pharmaceuticals gets USFDA nod for generic blood cancer treatment drug

Business Line

The approval by the USFDA is for the abbreviated new drug application (ANDA) of Dasatinib Tablets of strengths 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, Alembic Pharmaceuticals said in a regulatory filing